Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.
暂无分享,去创建一个
S. Shariat | P. Karakiewicz | S. Egawa | B. Pradère | P. Nyirády | H. Mostafaei | P. Rajwa | E. Laukhtina | F. Quhal | T. Yanagisawa | R. Motlagh | F. König | T. Kimura | T. Kawada | M. Pallauf
[1] J. Carles,et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design , 2022, The Lancet.
[2] F. Saad,et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. , 2022, The New England journal of medicine.
[3] M. Mitterhauser,et al. Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies , 2022, Molecular cancer.
[4] B. Sitek,et al. Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer , 2021, Journal of cellular and molecular medicine.
[5] S. Shariat,et al. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis , 2021, International Journal of Clinical Oncology.
[6] S. Culine,et al. Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial. , 2021, European urology.
[7] B. Tombal,et al. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study , 2021, ESMO open.
[8] H. Miyake,et al. Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents , 2021, International Journal of Clinical Oncology.
[9] N. Numao,et al. Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer , 2021, Cancer Chemotherapy and Pharmacology.
[10] M. Eklund,et al. Real world treatment utilization patterns in patients with castration-resistant prostate cancer , 2021, Scandinavian journal of urology.
[11] O. Sartor,et al. Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study , 2021, Cancers.
[12] A. D'Amico,et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.
[13] M. Stockler,et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial , 2021, The Lancet.
[14] Henk G van der Poel,et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. , 2020, European urology.
[15] J. Carles,et al. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. , 2020, The Lancet. Oncology.
[16] F. Pouliot,et al. Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. , 2020, European urology oncology.
[17] A. Fourrier-Réglat,et al. Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice. , 2020, Clinical genitourinary cancer.
[18] J. Pang,et al. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis , 2020, Prostate Cancer and Prostatic Diseases.
[19] F. Saad,et al. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. , 2020, Clinical genitourinary cancer.
[20] K. Kuroiwa,et al. Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study , 2020, Anti-cancer drugs.
[21] H. Miyake,et al. Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer. , 2019, Japanese journal of clinical oncology.
[22] A. Fourrier-Réglat,et al. Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort , 2019, British Journal of Cancer.
[23] N. Numao,et al. Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan , 2019, AntiCancer Research.
[24] M. Hendriks,et al. Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. , 2019, Clinical genitourinary cancer.
[25] J. Carles,et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.
[26] S. Sakamoto,et al. Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer , 2019, Urologia Internationalis.
[27] S. Shariat,et al. Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. , 2019, Clinical genitourinary cancer.
[28] H. Miyake,et al. Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer , 2019, AntiCancer Research.
[29] Liang Jin,et al. The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy , 2019, Journal of Cancer.
[30] E. Kikuchi,et al. No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer , 2018, Cancer Chemotherapy and Pharmacology.
[31] M. Oya,et al. Risk stratification of castration-resistant prostate cancer patients treated with cabazitaxel. , 2018, Molecular and clinical oncology.
[32] H. Miyake,et al. Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel , 2018, AntiCancer Research.
[33] M. Yao,et al. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel , 2018, BMC Cancer.
[34] F. Saad,et al. Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. , 2018, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[35] M. Parmar,et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] R. Hofheinz,et al. PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study , 2018, World Journal of Urology.
[37] R. Mathijssen,et al. Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel , 2017, Oncotarget.
[38] Yanqing Wang,et al. Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration‐resistant prostate cancer patients treated with abiraterone , 2017, The Prostate.
[39] M. Yao,et al. Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy , 2017, BioMed research international.
[40] W. Oh,et al. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting , 2017, Medical Oncology.
[41] S. Culine,et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. , 2016, European urology.
[42] C. Prado,et al. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later , 2016, Proceedings of the Nutrition Society.
[43] P. Kantoff,et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] A. Bergman,et al. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. , 2015, European journal of cancer.
[45] David F Jarrard,et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.
[46] E. Antonarakis,et al. Association of pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with first‐line docetaxel , 2014, BJU international.
[47] B. van Calster,et al. Prognostic impact of baseline serum C‐reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib , 2014, BJU International.
[48] S. Oudard,et al. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. , 2014, European journal of cancer.
[49] A. Armstrong,et al. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] G. Pond,et al. Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. , 2013, Future oncology.
[51] P. Giannakakou,et al. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. , 2012, Cancer research.
[52] C. Rock,et al. Nutrition and physical activity guidelines for cancer survivors , 2012, CA: a cancer journal for clinicians.
[53] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[54] J. Ioannidis,et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].
[55] Raghu Kacker,et al. Random-effects model for meta-analysis of clinical trials: an update. , 2007, Contemporary clinical trials.
[56] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[57] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[58] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[59] H. Yaegashi,et al. Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy , 2021, In Vivo.